The anti-TB prodrugs isoxyl (ISO) and thiacetazone (TAC) inhibit mycolic acid biosynthesis. Results: We show that ISO and TAC both target the dehydration step of the FAS-II elongation system. Conclusion: ISO and TAC share the same mode of action. Significance: ISO and TAC are the first antibiotics reported to target the FAS-II dehydratase(s) of Mycobacterium tuberculosis.
Isoxyl (ISO) and thiacetazone (TAC)
The prevalence of tuberculosis (TB) 6 and the increased incidence of multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis emphasize the need for new drugs with bactericidal mechanisms different from those of presently available agents. In this light, deciphering the mode of action of drugs that were formerly deemed effective against TB may prove useful in identifying new therapeutic targets and developing improved inhibitors targeting the same metabolic functions of the tubercle bacillus.
Isoxyl (ISO; thiocarlide) ( Fig. 1 ) was shown to have considerable antimycobacterial activity in vitro, displaying minimal inhibitory concentrations (MICs) against M. tuberculosis clinical isolates, including multidrug-resistant ones, in the range of 1-10 g ml Ϫ1 and a similar activity against atypical mycobacteria (1) . ISO was used in the treatment of TB in the 1960s but fell from clinical use due to untoward absorption kinetics and low bioavailability (2) (3) (4) . Thiacetazone (TAC) (Fig. 1) on the other hand is one of the oldest and least expensive drugs used in the clinical treatment of TB. Its MIC against M. tuberculosis isolates in vitro is in the range of 0.1-0.5 g ml Ϫ1 . However, toxicity issues, particularly in HIV patients, have restricted its clinical use (5) . ISO and TAC have in common inhibition of the synthesis of all forms of mycolic acids (MAs) in M. tuberculosis and a number of other Mycobacterium spp. through an as yet ill-defined mechanism (6 -10). Another distinctive feature of ISO and TAC is the fact that they are both prodrugs that require S-oxidation of their thiocarbonyl moiety by the flavin-containing monooxygenase EthA for antimycobacterial activity (8, 11, 12) . The active metabolites of TAC and ISO are not known.
Although the complete shutdown of the MA pathway that follows treatment with ISO and TAC has long been thought to account for their anti-TB activity (1, 6, 8 -10) , increasing evidence indicates that both drugs inhibit multiple other enzymes in mycobacteria, including the stearoyl-CoA ⌬9-desaturase DesA3 (7), ␣/␤-hydrolase fold mammalian-type epoxide hydrolases (13) , and S-adenosylmethionine (AdoMet)-dependent MA methyltransferases (9) . That the growth inhibition of M. tuberculosis by ISO and TAC results from effects on any of these targets is unlikely, however, given the dispensability of these enzymes for growth and the fact that that they are either not involved in MA biosynthesis or only involved at a late stage of their formation (Fig. 2) (7, 14, 15) . Instead, the dramatic effects of ISO and TAC on MA biosynthesis are consistent with both drugs inhibiting an early and essential step of the pathway, e.g. the elongation of the main (meromycolate) chain by FAS-II or the activation and condensation of the meromycolate and ␣-chains (16, 17) (Fig. 2) . Strong support for this hypothesis was recently obtained in the case of TAC with the identification of point mutations mapping to the (3R)-hydroxyacyl-ACP dehydratases (encoded by the hadABC genes) of the FAS-II elongation system (18) in spontaneous M. tuberculosis and Mycobacterium kansasii TAC-resistant isolates (10) .
With the broad long term goal of developing new chemotherapeutic agents with greater potency, reduced toxicity, and more desirable pharmacological features than ISO and TAC, here we used a combination of genetic and biochemical approaches to directly assess the inhibitory effect of TAC and ISO on the formation of MA in intact M. tuberculosis cells and identify the precise steps of the biosynthetic pathway interrupted by these drugs. Our results demonstrate that the two drugs share a novel and common mode of action on M. tuber- culosis, inhibiting MA synthesis at the level of the dehydratase step of FAS-II. 18 , 2.1 ϫ 150 mm, 5-m particle size) column heated to 45°C was used with a binary solvent system and a flow rate of 0.32 ml min Ϫ1 for the separation of the fatty acids. The separation was done using a gradient of 100% solvent A (99% CH 3 OH, 1% 500 mM ammonium acetate) to 100% solvent B (79% n-propyl alcohol, 20% hexane, 1% 500 mM ammonium acetate). The drying gas temperature was 300°C, and the vaporizer temperature was set at 200°C. The fragmentor voltage was set to 120 V. The mass spectrum was acquired from m/z 250 to 3200 with a frequency of one scan s
EXPERIMENTAL PROCEDURES
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. GC/MS Analysis-The same fatty acid samples as used for LC/MS analyses were further treated with 3 M HCl in CH 3 OH (Supelco) overnight at 80°C, dried, and dissolved in 50 l of N,O-bis(trimethylsilyl)trifluoroacetamide (Sigma). Samples were heated at 60°C for 10 min prior to injection for GC/MS. Analyses were carried out using a CP 3800 gas chromatograph (Varian) equipped with an MS320 mass spectrometer in the electron impact mode and scanning from m/z 50 to 1000 over 0.5 s. Helium was used as the carrier gas with a flow rate of 1 ml min Ϫ1 . The samples were run on a DB 5 column (10 m ϫ 0.20-mm inner diameter). The injector (splitless mode) was set for 335°C. The oven temperature was held at 50°C for 1 min, programmed at 30°C min Ϫ1 to 130°C, and then programmed at 10°C min Ϫ1 to 330°C followed by a 10-min hold. The data analyses were carried out on a Varian WS data station.
Recombinant Expression of Mycolic Acid Biosynthetic GenesThe hadA, hadAB, and hadBC genes from M. tuberculosis H37Rv; the hadABC genes from Mycobacterium smegmatis mc 2 155 and M. tuberculosis H37Rv; and the mmaA2 and mmaA4 genes from WT M. tuberculosis H37Rv, ISO-R2, ISO-R10, and ISO-R13 were expressed constitutively under control of the hsp60 promoter from the replicative plasmid pVV16 or pMVGH1 (14) . These plasmid constructs allow for the production of recombinant proteins harboring a C-terminal His 6 tag. Primer sequences and cloning strategies are available upon request. The pMV261 constructs used for the expression of other FAS-II genes were described elsewhere (10) . ISO-R2 and ISO-R10 were also complemented with a WT copy of mmaA4 expressed under control of its own promoter from the replicative plasmid pCG76.
Whole Genome Sequencing-Genomic DNA was isolated from freshly cultured M. tuberculosis H37Rv resistant isolates, and barcoded fragment libraries constructed for each of the strains were sequenced using SOLiD TM V3 chemistry (Applied Biosystems) as described (14) . The data were reduced to sequence, and reports about SNPs and indels were generated using NextGen Software.
RESULTS
TAC and ISO Display Bactericidal Activity in
Vitro-Although ISO and TAC have been most often reported in the literature as bacteriostatic agents (3, 5) , ISO for instance has also been shown to display bactericidal activity against M. tuberculosis residing within macrophages (1) . Given these apparent discrepancies, we first wanted to definitively answer the question of the bactericidal or bacteriostatic activities of TAC and ISO on in vitro grown M. tuberculosis for its relevance to the mode of action of those drugs. As shown in Fig. 1 , exposure of M. tuberculosis H37Rv (ATCC 25618) in log phase growth to 10 g ml Ϫ1 ISO or 17.5 g ml Ϫ1 TAC (corresponding to 2ϫ and 7ϫ MIC, respectively) resulted in a reduction in viable colony-forming units of about 2 log units after 3 days, indicating that these compounds are bactericidal in vitro. Their killing effect was about an order of magnitude less than that seen with isoniazid (INH) at 7ϫ MIC.
Effects of ISO and TAC on Mycolic Acid Elongation in Whole M. tuberculosis Cells-To gain insight into the precise steps of the MA biosynthetic pathway at which TAC and ISO acted, LC/MS-and GC/MS-based methods were designed to monitor the potential buildup of biosynthetic precursors in drug-treated M. tuberculosis cells. M. tuberculosis H37Ra (ATCC 25177) was used in these experiments as the absence of hydroxylated and non-hydroxylated long-chain fatty acids of the (hydroxy)phthioceranic, mycosanoic, mycolipenic, and mycolipanolic families from this strain (19) facilitated the detection of meromycolate precursors produced by the FAS-II system. Moreover, ISO and TAC display the same inhibitory effect on mycolic acid synthesis on M. tuberculosis H37Ra as they do on virulent M. tuberculosis isolates such as H37Rv (Fig. 3A) .
Actively growing bacteria were treated with either no drug (control), 7.5 g ml Ϫ1 ISO, or 10 g ml Ϫ1 TAC for 24 h, the cells were then harvested, and fatty acids were processed for LC/MS and GC/MS analyses. LC/MS revealed a dramatic buildup of a C 20 hydroxy fatty acid with an elemental composition (deduced from the exact mass of the [M Ϫ 1] Ϫ at 327.291) of C 20 H 40 O 3 following both ISO and TAC treatments. This component was essentially not present in the control with no drug (Fig. 3B) . That this was a 3-hydroxy C 20 fatty acid was shown by GC/MS (Fig. 3, C and D) . GC/MS also revealed the accumulation of 3-hydroxy C 18 , C 22 , and C 26 fatty acids, although the two latter forms did not build up as dramatically as 3-hydroxy C 18 and C 20 (Fig. 3C) . In addition to the buildup of these 3-hydroxy compounds, meromycolate precursors further down the FAS-II pathway decreased in the drug-treated cells as illustrated in supplemental Fig. S1 for monounsaturated C 34 and diunsaturated C 52 . A slight buildup of non-hydroxylated C 26 fatty acids was also noted in the treated cells, probably reflecting the accumulation of the ␣-alkyl C 26 fatty acid branch originating from FAS-I (7) (supplemental Fig. S2 ). The specific buildup of 3-hydroxy C 18 -C 22 fatty acids in drug-treated cells was thus consistent with ISO and TAC inhibiting the dehydratase step of the FAS-II elongation cycle (Fig. 2) .
Effects of Mutations in hadABC and of Modulating hadABC
Expression on the Susceptibility of M. tuberculosis to ISO and TAC-To assess whether HadABC potentially served as the targets of ISO and TAC, we undertook to study the effect of overexpressing the corresponding genes on the MIC of both drugs against M. tuberculosis H37Rv. The had genes were expressed either individually or in different combinations as both the heterodimers HadAB and HadBC were reported to be involved in the dehydratase step of FAS-II, the former apparently acting on shorter MA precursors than the latter (18) . Production of recombinant proteins from the pVV16 and pMVGH1 constructs was verified by immunoblotting with monoclonal anti-His antibodies (data not shown). Similar to the situation recently described for TAC (10) and reproduced here, our results showed a clear effect of overexpressing had-ABC (both the M. tuberculosis and M. smegmatis orthologs) Ϫ at 327.291) in the drug-treated cells. C, GC/MS analysis of the trimethylsilylated fatty acids prepared from the same untreated and drug-treated cells as in B. Shown are the ion traces at m/z 175 (which is diagnostic for 3-hydroxy fatty acids) in the absence (no drug) and presence of ISO and TAC. Note the increase in 3-hydroxy C 18 , C 20 , C 22 , and to a lesser extent C 24 and C 26 fatty acids in drug-treated samples compared with the control. In B and C, the same volume of samples prepared from an equivalent amount of treated and untreated cells was analyzed. In the histogram, the percent areas of the hydroxy fatty acids of interest to the total areas of the GC/MS chromatograms in the ISO-(white bars) and TAC (gray bars)-treated cells was compared with that of the corresponding fatty acids in the untreated cells (black bars), and values were expressed as -fold increase over the untreated cell values arbitrarily set to 1 for each hydroxy fatty acid species. D, the structure of the 3-hydroxy C 20 fatty acid as determined by GC/MS after formation of the methyl ester and trimethylsilylation of the alcohol.
and hadBC on the susceptibility of M. tuberculosis to ISO (Ͼ16-fold increase in MIC) with no significant effect of overexpressing hadAB or the individual hadA, -B, and -C genes (Table 1) . This increase in MIC was specific to the dehydratases as overexpression of other FAS-II genes such as inhA, kasA, and mabA had no significant impact on the susceptibility of M. tuberculosis to ISO (Table 1 ) and TAC (10) .
Interestingly, an M. tuberculosis CDC1551 mutant harboring a transposon insertion after bp 1 of hadC (Biodefense and Emerging Infectious Research Resources Repository Resources mutant NR-18624) was found to be 50 -100-fold more susceptible to ISO and 40 -80-fold more susceptible to TAC than WT M. tuberculosis CDC1551 ( Table 1 ). The buildup of 3-hydroxy C 18 in the transposon mutant that accompanied an overall decrease in downstream FAS-II elongation products identified as diunsaturated C 43 to C 54 fatty acids (supplemental Fig. S3 ) is suggestive of a reduced dehydratase enzymatic activity in this strain compared with WT M. tuberculosis CDC1551. Further supporting an impact of HadABC on ISO susceptibility, spontaneous TAC-resistant isolates of M. tuberculosis and M. kansasii harboring missense mutations in their hadA (C61S) and hadC (V85I) genes (10) were also found to be more than 25-fold more resistant to ISO (Table 1) . Another M. tuberculosis mutant harboring a missense mutation at position 121 of HadC (A151V) was only 5-fold more resistant to ISO than WT M. tuberculosis H37Rv, whereas it was 40 -100-fold more resistant to TAC (10) .
Isolation and Characterization of Spontaneous ISO-resistant Mutants of M. tuberculosis and Mycobacterium bovis BCG-In
an independent approach to identify the targets of ISO in the MA pathway, spontaneous ISO R mutants of M. tuberculosis and M. bovis BCG were isolated and the whole-genome sequence of the M. tuberculosis H37Rv isolates compared with that of their WT parent. M. tuberculosis H37Rv ISO R isolates were selected as described earlier (11) . The M. bovis BCG ISO R isolates were selected on 7H11-OADC plates containing 1.25-10 g ml Ϫ1 ISO (2.5-10ϫ MIC) at 32°C rather than 37°C to facilitate the growth of potential mutants with defects in the MA pathway. Selection was performed in the presence of oleic acid in the medium to avoid selecting isolates carrying mutations in the stearoyl-CoA ⌬9-desaturase DesA3. Five M. tuberculosis H37Rv ISO R isolates (ISO-R1, ISO-R2, ISO-R10, ISO-R12, and ISO-R13) found not to harbor any mutations in their ethA and ethR (i.e. an ethA repressor) genes were picked for further drug susceptibility testing and whole-genome sequencing. The M. bovis BCG isolate showing the greatest level of resistance to ISO (BCG-R5) ( Table 2 ) while displaying WT ethA and ethR sequences was also selected for further studies. Although the MICs of INH, ethambutol, and rifampicin against all ISO R isolates were similar to those measured for WT M. tuberculosis H37Rv and M. bovis BCG, all six isolates were found to be Ͼ8 -16-fold more resistant to TAC (Table 2) .
Comparative whole-genome sequencing of WT M. tuberculosis H37Rv, ISO-R1, ISO-R2, ISO-R10, ISO-R12, and ISO-R13 failed to identify a single gene commonly affected in all ISO R isolates. In particular, no mutation was found in the promoter region or coding sequences of their hadABC genes. However, mutations were found in the AdoMet-dependent MA methyltransferase gene mmaA2 of ISO-R13 (in-frame deletion of nucleotides A482, T483, and G484 resulting in the loss of residue Asp-161) and in the mmaA4 gene of ISO-R2 and ISO-R10 (frameshift mutations at positions G748 and T646 resulting in truncated MmaA4 proteins missing 30 and 83 residues, respectively). The six other AdoMet-dependent MA methyltransferase genes of M. tuberculosis H37Rv (mmaA1, mmaA3, pcaA, cmaA1, cmaA2, and umaA) were double checked by PCR and sequencing and found to display WT sequences in all 5 M. tuberculosis ISO R isolates. In contrast to the situation in M. tuberculosis, PCR amplification and sequencing of the promoter regions and coding sequences of the hadABC genes of BCG-R5 identified a missense mutation in hadA (182G3 C) resulting in an amino acid change (C61S). Strikingly, this mutation was identical to that reported earlier in TAC R mutants of M. tuberculosis and M. kansasii (10) ( Table 1) . That this point Table 1 , only the expression of the mutated allele increased the resistance of M. tuberculosis H37Rv to ISO (Ͼ80-fold increase in MIC over the WT parent strain). The resistance of M. tuberculosis H37Rv to TAC was also increased more than 50-fold by the expression of the mutated hadA allele (Table 1) .
Investigations on the Role of mmaA4 and mmaA2 in the Susceptibility of M. tuberculosis H37Rv to ISO and TAC-Consist-
ent with the presence of mutations in mmaA4, ISO-R2 and ISO-R10 were dramatically affected in oxygenated MA production (Fig. 4) . ISO-R13 on the other hand, although proficient in the biosynthesis of all three families of MA, produced less of the methoxy form (Fig. 4) . As expected, MA synthesis in ISO-R10 (as well as ISO-R1 and ISO-R12) was resistant to ISO treatment, suggestive of normal FAS-II dehydratase activity in the treated mutant cells (supplemental Fig. S4) . That the increased level of resistance of ISO-R2 and ISO-R10 to ISO and TAC is consecutive to changes in their MA content affecting the permeability of their cell envelope is unlikely given the unchanged MICs of other drugs against these mutants (Table 2 ) and the fact that the complementation of ISO-R2 and ISO-R10 with a WT copy of mmaA4 expressed in trans from a multicopy plasmid, although restoring the synthesis of oxygenated mycolates to WT levels (supplemental Fig. S5 ), did not increase their susceptibility to ISO (Table 3) .
To investigate whether, similar to the situation with had-ABC, modulating the level of expression of mmaA2 and mmaA4 or expressing mutated alleles of these genes affected the susceptibility of M. tuberculosis to ISO and/or TAC, the WT mmaA4 and mmaA2 genes and mutated alleles expressed by ISO-R2 (mmaA4-R2), ISO-R10 (mmaA4-R10), and ISO-R13 (mmaA2-R13) were constitutively expressed in M. tuberculosis H37Rv from a multicopy plasmid under control of the hsp60 promoter. Because of the toxic effect of overexpressing mma2 and mmaA4, MICs were determined by directly plating the transformants onto agar medium containing increasing concentrations of ISO or TAC. Concomitantly, the susceptibility of an mmaA4-null mutant of M. tuberculosis (M. tuberculosis H37Rv⌬mmaA4) (20) to ISO and TAC was determined. MIC determinations clearly showed that knocking out the mmaA4 gene of M. tuberculosis H37Rv only increased the resistance of this bacterium to ISO 4-fold (Table 3) . In contrast and consistent with an earlier report about TAC resistance in M. bovis BCG (21), the disruption of mmaA4 in M. tuberculosis increased more than 50-fold the resistance of this species to TAC. Overexpression of mmaA4 and mmaA2 (either WT or mutated) in WT M. tuberculosis H37Rv had no clear impact on the MICs of ISO and TAC other than in some cases to slightly increase the susceptibility of M. tuberculosis to both drugs; however, it is not clear to what extent the toxicity associated with the overexpression of those methyltransferases may have accounted for this effect given that both the WT and mutated alleles of mmaA4 slightly increased the susceptibility of M. tuberculosis to ISO and TAC.
In light of the hypothesis formulated earlier that MmaA4 may serve as an activator of TAC (21), we tested whether the incubation of ISO or TAC with purified MmaA4 in the presence or absence of purified EthA in vitro led to the generation of metabolites of these drugs. Although the exposure of ISO and TAC to purified EthA led to the formation of the expected metabolites of those drugs (11, 12) , results failed to reveal any clear metabolizing activity of MmaA4 and any additional activity of MmaA4 beyond that of EthA (supplemental Fig. S6 ).
DISCUSSION
Biochemical and genetic evidence presented herein is consistent with ISO and TAC, two drugs once deemed efficient in the clinical treatment of TB, abolishing MA biosynthesis through the inhibition of the dehydratase step of FAS-II. Treating M. tuberculosis with these drugs led to a marked accumulation of 3-hydroxy C 18 , C 20 , and C 22 fatty acids that accompanied a shutdown of FAS-II elongation products beyond the formation of these hydroxylated meromycolate precursors. ISO and TAC can thus unambiguously now be added to the list of 14 C]Acetate-derived ␣-, methoxy-, and keto-MA methyl esters were prepared from delipidated cells as described previously (1, 14) , analyzed by TLC in the solvent system (n-hexanes:ethyl acetate, 95:5; three developments), and revealed by autoradiography. The same number of total cpm was loaded per lane. drugs targeting the FAS-II elongation system of M. tuberculosis. In addition, they are the first clinically used anti-TB drugs reported to act at the dehydration step. Consistent with their mode of action and similar to INH, ISO and TAC display bactericidal activity on actively replicating M. tuberculosis in vitro.
At the molecular level, given the complexity of the MA biosynthetic machinery, which relies on multiprotein complexes wherein protein interactions govern the elongation and modification of the meromycolate chain (22) (23) (24) , it is at present not possible to definitively conclude whether ISO and TAC preferentially inhibit HadAB or HadBC and whether they inhibit this (these) enzyme(s) directly (e.g. by competing for their substrate-binding sites) or through a less direct mechanism (e.g. by perturbing heterotypic interactions involving HadAB/BC and other MA biosynthetic enzymes). The importance of protein interactions within the FAS-II interactome was clearly illustrated by the work of Veyron-Churlet et al. (22) (23, 24) . In this light, it is tempting to speculate that affecting the level of expression or primary sequence of these MA methyltransferases may impact the structure of the FAS-II interactome in a way that prevents ISO and TAC from effectively binding to the dehydratases. In the case of MmaA4 at least, we favor this hypothesis over that formulated earlier that MmaA4 (and perhaps other MA methyltransferases) acts as an activator of TAC and possibly ISO (21) for two reasons. One reason is the apparent lack of activity of MmaA4 on ISO and TAC in vitro whatever the assay conditions tested here, although other proteins or cofactors may be required for MmaA4 to become active. The second reason is the fact that ISO displays bactericidal activity against M. tuberculosis (albeit at a 4-fold higher concentration) even in the absence of a functional MmaA4 enzyme in the cells. Whatever may be the precise molecular mechanisms of inhibition of ISO and TAC and mechanisms of resistance of M. tuberculosis to these drugs, it is likely that their reconstitution in vitro will require the presence of enzymes other than only the dehydratases. Despite the striking similarities displayed by TAC and ISO in their bactericidal mechanism, a few notable differences were noted in the way their MICs against M. tuberculosis responded to WT and mutated gene expression, suggestive of slightly different molecular mechanisms of action. First is the fact that an M. tuberculosis mutant harboring a missense mutation at position 151 of HadC (Ala 3 Val) was 40 -100-fold more resistant to TAC but only 5-fold more resistant to ISO than WT M. tuberculosis H37Rv (Table 1) . Second, overexpression of hadAB resulted in a slight increase in the resistance of M. tuberculosis to TAC (5-fold), whereas it had no detectable effect on ISO susceptibility (Table 1) (10) . Third, whereas the expression of an active MmaA4 enzyme is absolutely required for TAC to exert its bactericidal activity on BCG and M. tuberculosis (Refs. 10 and 21 and this study), this is clearly not the case for ISO whose MIC against M. tuberculosis only increased 4-fold upon mmaA4 inactivation (Table 3) . Fourth, the treatment of M. bovis BCG with TAC or ISO was reported to affect differently the MA content of this bacterium with TAC treatment leading to the clear accumulation of an unsaturated ketomycolate precursor that was not seen in ISO-treated cells (8, 9) . This difference in activity was attributable to the likely (direct or indirect) inhibitory activity of TAC on AdoMet-dependent MA methyltransferases in M. bovis BCG, an effect not applicable to ISO. Altogether, these results are consistent with TAC and ISO occupying slightly different binding sites on the FAS-II interactome with the inhibitory activity of TAC on the dehydratases requiring the presence of an intact MmaA4 unlike that of ISO. Future experiments will now focus on understanding at the molecular level the interactions of ISO and TAC with the FAS-II interactome and their precise mechanism of inhibition of HadAB and/or HadBC.
